Solitary Epicranial Neurofibroma with Neurofibromatosis Type 1-Related Germline Mutation: Case Report

Natsuki SUGIYAMA,1 Satoshi TSUTSUMI,1 Chihiro AKIBA,1 Hajime NAKANISHI,1 Ikuko OGINO,2 Yukimasa YASUMOTO,1 Hajime ARAI,2 and Masanori ITO1

1Department of Neurological Surgery, Juntendo University Urayasu Hospital, Urayasu, Chiba; 2Department of Neurological Surgery, Juntendo University School of Medicine, Tokyo

Abstract
A 33-year-old male became aware of a painless soft mass in the left occipital region. His medical and family history were unremarkable for neurofibromatosis type 1 (NF1) or other genetic disorders. Physical examination showed no signs of NF1. Neurological and ophthalmological examinations found no abnormality. Cranial computed tomography showed an isodense mass located subcutaneously with irregular deformities in the adjacent occipital bone. Magnetic resonance (MR) imaging demonstrated that the lesion, 7.5 × 5.5 cm in diameter, was hypointense both on T1- and T2-weighted images and intensely enhanced after gadolinium infusion. The patient requested to remove the large mass. The subcutaneous tumor was well circumscribed, encapsulated, and less vascular, and resected en bloc. The histological diagnosis was neurofibroma without findings of cell atypia, whereas genomic exploration identified abnormal gains in NF1 gene, and resultant absence of neurofibromin, a protein coded on NF1 gene. Solitary neurofibromas in “clinically” non-NF1 patients may originate from the genomic changes in NF1 gene.

Key words: epicranial neurofibroma, neurofibromatosis, germline mutation

Introduction
Neurofibromas are benign tumors arising from the peripheral nerve sheath and are characterized by proliferation of Schwann cells, perineural cells, and fibroblasts. Microscopically they are composed of elongated, spindle-shaped cells with round or fusiform nuclei and eosinophilic cytoplasm within a loose matrix of fine fibrillar collagen.1) Historically, neurofibromas have been divided into subtypes according to different classifications on the basis of the mode of tumor extension,2) histological characteristics,3) or anatomical locations in the cutaneous and subcutaneous layer.4) Neurofibroma in the head region is uncommon.5–11) A fraction of these tumors develop massive intratumoral hemorrhage5–8) and malignant transformation.12) Most cases of epicranial neurofibromas and other neurofibromas originating in the head region were associated with neurofibromatosis type 1 (NF1), a genetic disorder at 17q11.2, an oncosuppressor gene coding neurofibromin and acting on the ras-related system.6,8–10) In contrast, only 3 cases of neurofibromas that are not associated with NF1 have been documented.7,8,10) Those diagnoses were based on the conventional clinical criteria for NF1, and genetic exploration has not been performed so far. Here we present a unique case of solitary epicranial neurofibroma in an adult male with no clinical association with NF1, but with genetic indications of NF1-related germline mutation.

Case Report
A 33-year-old male was aware of a painless soft mass in the left occipital region for 2 months. His medical history was unremarkable without mental retardation, family history of NF1, or other genetic disorders. The patient had not been aware of any subcutaneous mass in the occipital region or any preceding head trauma. At presentation, he had no macules, freckles, or tumors of the skin. The spinal alignment was normal without deformity. Neurological and ophthalmological examinations did not find any abnormalities. Cranial computed tomography showed an isodense mass located subcutaneously associated with irregular deformities in the outer surface of the adjacent occipital bone (Fig. 1). Magnetic resonance (MR) imaging demonstrated that the lesion
appeared hypointense on both T₁- and T₂-weighted images, was 7.5 × 5.5 cm in diameter, entirely located epicranially, and intensely enhanced after gadolinium infusion. No concurrent intracranial or orbital tumor was found (Fig. 2).

The patient requested to remove the large mass. He underwent tumor resection with the presurgical diagnosis as lipoma, fibroma, neurofibroma, and myogenic tumor. The subcutaneous tumor was elastic, soft, well circumscribed, entirely encapsulated, and less vascular, with firm adhesion to the periosteum, so was dissected circumferentially and resected on bloc (Fig. 3). The main trunk of the left occipital artery coursed above and supplied small tributaries to the tumor capsule. Macroscopically, the sections of the tumor were homogeneous and did not contain hematoma. Histological examination found spindle-shaped tumor cells with round or fusiform nuclei and eosinophilic cytoplasm within a matrix of fine fibrillary collagen consistent with neurofibroma. Immunohistochemical staining for tumor cells was positive for S-100 protein, but negative for CD34. The Ki-67 labeling index was less than 1%. No cell atypia, endothelial proliferation, or intratumoral hemorrhage was found (Fig. 4).

Genomic exploration was carried out by the single nucleotide polymorphism (SNP) method. The genomic deoxyribonucleic acid was extracted from paraffin-embedded tissue blocks using Puregene Core Kit A (QIAGEN, Hilden, Germany). Then SNP oligonucleotide microarray analysis was performed with the Affymetrix Gene Chip Human Mapping 6.0 SNP array (Affymetrix, Santa Clara, California, USA). Sample preparation, hybridization, and scanning were performed according to the manufacturer’s specifications. Data were analyzed with Genotyping Console v2.0 (Affymetrix) and Ingenuity Pathway Analysis v7.5 (Ingenuity Systems, Redwood City, California, USA), which confirmed abnormal gains in NF1 gene (Fig. 5A). Immunohistochemical staining for neurofibromin, a protein coded on 17q11.2, was absent (Fig. 5B). No abnormalities in the neurofibromatosis type

Neurol Med Chir (Tokyo) 54, April, 2014
2 (NF2) gene, located on the 22q11.23, were found. These findings were indicative of neurofibroma originating from germline mutation in NF1 gene.

Discussion

In the present case, solitary epicranial neurofibroma occurring in a young adult male appeared to be clinically non-NF1 based on the normal cutaneous, ocular, and skeletal findings without brain or orbital tumor, in addition to the unremarkable family history of NF1. Review of epicranial neurofibromas found extraordinarily slow progression and predisposition for the occipital region, with manifestation as skull defect or thinning, and hypervascularity. Intraoperative findings revealed an encapsulated epicranial tumor with deformities in the adjacent skull. The histological appearance of the tumor was indicative of benign pathology with low mitotic activities, no cell atypia, and no intratumoral hemorrhage. These findings were consistent with typical neurofibroma manifesting after extraordinarily indolent growth. In contrast, genetic exploration was indicative of a tumor originating from NF1-related germline changes.

Neurofibromatoses are commonly diagnosed based only on the clinical manifestations and may miss “clinically silent” cases, which are genetically evident as neurofibromatoses. This possibility implies that the “clinical” definition of neurofibromatosis may not cover the entire spectrum of this disease and emphasizes the possibility of more diverse pathophysiology.

The exact genesis of neurofibromas is not well understood, but recent investigation has suggested that the hair follicle apparatus, including the nerve tributaries, may be

Fig. 4 Photomicrographs of the resected tumor showing spindle-shaped cells with round or fusiform nuclei and eosinophilic cytoplasm within a matrix of fine fibrillary collagen, without findings of cell atypia, endothelial proliferation, or intratumoral hemorrhage (A: hematoxylin and eosin [HE] stain). Immunohistochemical staining for tumor cells was positive for S-100 protein (B), but negative for CD34 (C). Ki-67 labeling index was less than 1% (D). Original magnification ×50 (A–D). A: HE, ×50; B: S-100, ×50; C: CD 34, ×50; D: MIB-1< 1%.

Fig. 5 A: Genomic exploration by the single nucleotide polymorphism identification method showing abnormal gains in NF1 gene (17q11.2) (arrows). B: Immunohistochemical staining for neurofibromin demonstrating negative staining. Original magnification ×10.
Solitary Epicranial Neurofibroma

an origin of NF1-associated cutaneous neurofibromas.\(^9\) Recently Beert et al. described a pediatric case of sporadic neurofibroma arised in the lumbosacral region without signs of NF1. They concluded on the basis of genomic analysis that biallelic NF1 gene inactivation may be the underlying pathomechanism.\(^{10}\) Germline mutations in NF1 may include diverse spectrum with cases not presenting signs of NF1. Similarly, germline changes of the SMARCB1 gene, also called BAF47 or hSNF5, which is located at 22q11.23 and functions as a chromatin remodeling gene, may be a locus of familial and sporadic NF2 that originates from changes at 22q12.2.\(^{14–16}\) In the present patient, no germline mutations were identified at 22q12.2.

Solitary neurofibromas in “clinically” non-NF1 patients may originate from germline changes in NF1 gene. Further genetic investigation combined with more case experience can provide updated diagnostic criteria including the germline mutations of neurofibromatoses, which would be useful for better delineating the genesis, pathophysiology, and biological behavior of neurofibromas.

Conflicts of Interest Disclosure

The authors have no personal, financial or institutional interest in any of the drugs, materials, or devices in the article. All authors who are members of the Japan Neurosurgical Society (JNS) have registered online self-reported conflict of interest disclosure statement forms through the website for JNS members.

References

1) Yoo KH, Kim BJ, Rho YK, Lee JW, Kim YJ, Kim MN, Song KY: A case of diffuse neurofibroma of the scalp. Ann Dermatol 21: 46–48, 2009
2) Beggs I, Gilmour HM, Davie RM: Diffuse neurofibroma of the ankle. Clin Radiol 53: 755–759, 1998
3) Coakley D, Atlas MD: Diffuse neurofibroma obstructing the external auditory meatus. J Laryngol Otol 111: 145–147, 1997
4) Evans D, Komminoth P, Scheihauler B, Peltonen J: Neurofibromatosis type 1, in DeLeiris R, Lloyd R, Heitz P, Eng C (eds): Pathology and Genetics of Tumours of Endocrine Organs: World Health Organization Classification of Tumours. Lyon, IARC Press, 2004, pp 243–248
5) Bhaskar S, Sobti S, Singh AK: Massive scalp hematoma due to diffuse neurofibroma in NF-1. Clin Neurol Neurosurg 115: 477–480, 2013
6) Garcia-Uria J, Sola RG, Carrillo R, Bravo G: Epicranial plexiform neurofibroma. Surg Neurol 11: 390–392, 1979
7) Ohaegbulam SC: “Congenital” plexiform neurofibroma of the occipital scalp. Case report. J Neurosurg 46: 245–247, 1977
8) Scott M: Massive plexiform neurofibroma of the occipital scalp. Case report. J Neurosurg 25: 81–82, 1966
9) Tsutsumi M, Kazekawa K, Tanaka A, Ueno Y, Nomoto Y, Nii K, Haraoka S: Rapid expansion of benign scalp neurofibroma caused by massive intratumoral hemorrhage—case report. Neurol Med Chir (Tokyo) 42: 338–340, 2002
10) Wakuta Y, Mitani T: Giant epicranial neurofibroma—case report. Neurol Med Chir (Tokyo) 28: 690–694, 1988
11) Yoshida Y, Shindo M, Yamamoto O: Occipital bone dysplasia associated with diffuse plexiform neurofibroma. Eur J Dermatol 21: 452–453, 2011
12) Jouhilatzi EM, Peltonen S, Callens T, Jokinen E, Heape AM, Messiaen L, Peltonen J: The development of cutaneous neurofibromas. Am J Pathol 178: 500–505, 2011
13) Beert E, Brems H, Renard M, Ferreiro JF, Melotte C, Theolen R, De Wever I, Sciot R, Legius E, Debiec-Rychter M: Biallelic inactivation of NF1 in a sporadic plexiform neurofibroma. Genes Chromosomes Cancer 51: 852–857, 2012
14) Hadfield KD, Newman WG, Bowers NL, Wallace A, Bolger C, Colley A, McCann E, Trump D, Prescott T, Evans DG: Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet 45: 332–339, 2008
15) Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P: Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet 80: 805–810, 2007
16) Rousseau G, Noguchi T, Bourdon V, Sobol H, Olshzwang S: SMARCB1/INI1 germline mutations contribute to 10% of sporadic schwannomatosis. BMC Neurol 11: 9, 2011

Address reprint requests to: Satoshi Tsutsumi, MD, Department of Neurological Surgery, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, Chiba 279-0021, Japan. e-mail: neuro1969@yahoo.co.jp

Neurol Med Chir (Tokyo) 54, April, 2014